spacer
home > ict > autumn 2017 > restricting regulations
PUBLICATIONS
International Clinical Trials

Restricting Regulations

Contemporary medicine has come a long way since the days of snake oil salesmen. Today, patients can be assured that prescribed medicine has been vetted for safety and efficacy through a long and arduous process, guided by governmental regulatory agencies. The central pillar of this rigorous procedure for current drug approval is the human clinical trial, the success of which has resulted in a proliferation of studies worldwide. Since the international committee of medical journal editors established trial registration requirements in 2005, enrolment has increased fivefold (1). In the US alone, clinical trial registration has increased tenfold during this same time period, but, against this backdrop, the EU recorded a concerning 25% decrease in clinical trial applications (CTA) from 2007 to 2011 (2).

Global Trials

One of the issues affecting the number of EU studies is a growing trend towards globalisation, with a recent rise in those conducted in developing countries. For example, the number of countries serving as study locations outside the US has more than doubled in the past 10 years, and the proportion of trials undertaken there and in Western Europe has reduced significantly (3,4).

Several factors drive this globalisation trend – one of them being the spiralling drug development costs. A 2013 study by the Tufts Center for the Study of Drug Development estimates the average expense to develop and gain market approval for a new therapeutic is $2.6 billion – up 145% from a similar investigation conducted in 2003 – with time costs accounting for half of that amount. The time and investment required to conduct trials is the largest contributor to these increases, and, given that the success rate for medications moving through clinical trials to FDA approval is a mere 10%, the pharmaceutical industry is struggling to sustain profitability (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Morgan is Head of Marketing at goBalto, a life sciences software as a service technology organisation. He works with sponsors, CROs, medical device manufacturers and sites to reduce cycle times and improve collaboration and oversight in clinical trials. Craig is a technology and life sciences management professional, with over 15 years’ experience in informatics and bioinformatics applications to drug discovery. He holds degrees in analytical chemistry, information systems and business administration and is a certified
spacer
Craig Morgan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fifth Annual Peptides Congress: Registration Now Open

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress, 16-17 April 2018 in London to shape the future of industry discussion. With over 700 peptides in clinical trials and an increasing industry focus on biologics, now more than ever is the time to focus on this revolutionary field!
More info >>

White Papers

Case Study: Emerade® Auto-Injector

SHL Group

The Emerade® Auto Injector is an intuitive disposable 2-step auto injector designed to deliver adrenaline via intramuscular injection during emergency use. The exterior of the device has a simple and sleek industrial design with the aim to minimize confusion for users. To achieve the penetration force required for an intramuscular injection while still ensuring the dosage is delivered correctly and needle protection mechanisms are in place, the Emerade Auto Injector is equipped with an advanced 3 spring technology. The device is also available in 3 doses (150mcg, 300mcg, 500mcg), with each recommended for patients of different bodyweights to maximize efficacy.
More info >>

 
Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement